Search 

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. We are headquartered in Nottingham, England with approximately 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company known for its expertise in nonclinical safety toxicology and ion channel electrophysiology.  The company is founded on the skills and experience of a growing team with a wide range of expertise in preclinical drug safety.

The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners.  There are many more SMEs who also need access to specialised services.

ApconiX addresses both needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way.  In this way, companies work with people they trust, to make better decisions on drug safety.

The market need has been demonstrated by the remarkable growth of ApconiX. The current client list is spread across the globe.
ApconiX has embarked on several strategic international alliances.  In collaborating with the French company PhysioStim, ApconiX has become part of a European centre of excellence for preclinical cardiovascular safety evaluation.  

ApconiX is continually forming collaborative relationships, helping customers large and small. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate the difficult pathway towards safe, effective and profitable drugs.

Aptus Clinical is a clinical research provider formed by three former AstraZeneca colleagues who have over 75 years’ combined drug development experience.



Our mission is to be the partner of choice for biopharmaceutical companies and academic researchers, supporting them in their quest to develop new and valued medicines. We understand the challenges faced by our clients and will provide key insight and experience to meet the needs of our customers by delivering operational excellence in order to achieve the exacting standards of the industry

 

With experience ranging from early methodology studies and first time in man, through proof of concept to Phase III registration and clinical pharmacology studies this  breadth and depth of knowledge is at the disposal of our customers.



We recognise that the increasing legislative, regulatory, ethical and patient focused expectations being placed on the conduct of clinical studies, is making their successful conduct and delivery ever more costly and difficult to achieve.



With this in mind, Aptus Clinical is continually developing a team of highly experienced clinical research experts who have extensive insight into the effective delivery of studies and are passionate about partnering with biotechs, pharma and academia to provide bespoke clinical delivery solutions.



Whether you are a company or academic institution looking for strategic input to study designs or need access to flexible, cost effective and experienced clinical research resources to deliver high quality studies, then please get in touch.

Arecor is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.